References
- GemmellCGEdwardsDIFraiseAPGouldFKRidgwayGLWarrenREJoint Working Party of the British Society for Joint Working Party of the British Society for Antimicrobial Chemotherapy, Hospital Infection Society and Infection Control Nurses AssociationGuidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UKJ Antimicrob Chemother20065758960816507559
- LiuCBayerACosgroveSEClinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summaryClin Infect Dis20115228529221217178
- MacGowanAPPharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptidesTher Drug Monit1998204734779780121
- MacGowanAPBowkerKEPharmacodynamics of antimicrobial agents and rationale for their dosingJ Chemother1997964739248964
- WeinbrenMStruthersKEmergence of Staphylococcus aureus (MRSA) with reduced susceptibility to teicoplanin during therapyJ Antimicrob Chemother20025030630712161421
- UedaTTakesueYNakajimaKEvaluation of teicoplanin dosing designs to achieve a new target trough concentrationJ Infect Chemother20121829630222065089
- MatsumotoKKanazawaNIkawaKDetermination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infectionsJ Infect Chemother20101619319920195882
- BrinkAJRichardsGACumminsRRRecommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsisInt J Antimicrob Agents20083245545818718742
- PeaFVialePCandoniATeicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosagesClin Pharmacokinet20044340541515086277
- RybakMLomaestroBRotschaferJCTherapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases PharmacistsAm J Health Syst Pharm200966829819106348
- SeniorJRMonitoring for hepatotoxicity: what is the predictive value of liver “function” tests?Clin Pharmacol Ther20098533133419129750
- WangJTLiaoHIWu LinFLChangSCLoading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infectionsBasic Clin Pharmacol Toxicol201211041642022309355
- LamontESeatonRAMacphersonMSempleLBellEThomsonAHDevelopment of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programmeJ Antimicrob Chemother20096418118719411678
- MimozORollandDAdounMSteady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumoniaIntensive Care Med20063277577916550370
- PeaFBrolloLVialePPavanFFurlanutMTeicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading doseJ Antimicrob Chemother20035197197512654757
- SvetitskySLeiboviciLPaulMComparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysisAntimicrob Agents Chemother2009534069407919596875
- Van der AuweraPMeunierFIbrahimSKaufmanLDerdeMPTulkensPMPharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infectionAntimicrob Agents Chemother1991356406472069370
- YoshidaMMatznoSNambaHNishikataMMatsuyamaKStatistical analysis of the adverse effects of glycopeptide antibiotics, based on pharmacokinetics and toxicokinetics (PK/TK)J Infect Chemother20061211411816826342
- FryeRFJobMLDretlerRHRosenbaumBJTeicoplanin nephrotoxicity: first case reportPharmacotherapy1992122402421535125
- WilsonAPRGrunegergRSafetyTeicoplanin; The First DecadeAbingdon, UKThe Medicine Group (Education) Ltd1997137144